1OT Stock Overview
A biopharmaceutical company, engages in the development of impactful medicines for patients and families with epilepsies and seizure-related neurological disorders in the United States. More details
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 2/6 |
| Past Performance | 0/6 |
| Financial Health | 5/6 |
| Dividends | 0/6 |
Rewards
Risk Analysis
+ 2 more risks
My Notes
Capture your thoughts, links and company narrative
Ovid Therapeutics Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$0.94 |
| 52 Week High | US$3.62 |
| 52 Week Low | US$0.61 |
| Beta | 0.29 |
| 1 Month Change | -3.08% |
| 3 Month Change | -1.05% |
| 1 Year Change | -69.71% |
| 3 Year Change | -67.86% |
| 5 Year Change | -77.17% |
| Change since IPO | -91.90% |
Recent News & Updates
Recent updates
Shareholder Returns
| 1OT | DE Biotechs | DE Market | |
|---|---|---|---|
| 7D | 0% | -3.5% | -2.0% |
| 1Y | -69.7% | -14.7% | 6.9% |
Return vs Industry: 1OT underperformed the German Biotechs industry which returned -14.7% over the past year.
Return vs Market: 1OT underperformed the German Market which returned 6.9% over the past year.
Price Volatility
| 1OT volatility | |
|---|---|
| 1OT Average Weekly Movement | 9.3% |
| Biotechs Industry Average Movement | 6.8% |
| Market Average Movement | 4.9% |
| 10% most volatile stocks in DE Market | 11.3% |
| 10% least volatile stocks in DE Market | 2.4% |
Stable Share Price: 1OT's share price has been volatile over the past 3 months compared to the German market.
Volatility Over Time: 1OT's weekly volatility has decreased from 15% to 9% over the past year, but is still higher than 75% of German stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2014 | 25 | Jeremy Levin | www.ovidrx.com |
Ovid Therapeutics Inc., a biopharmaceutical company, engages in the development of impactful medicines for patients and families with epilepsies and seizure-related neurological disorders in the United States. The company is developing soticlestat, a novel cholesterol 24 hydroxylase inhibitor, which is in Phase 3 clinical trials for the potential treatment of patients with resistant epilepsies; OV329, a GABA aminotransferase inhibitor which is in Phase 1 clinical trials for the treatment of seizures associated with tuberous sclerosis complex and infantile spasms; and OV350, a small molecule direct activator of the KCC2 transporter, which is in Phase 1 clinical trials for treating epilepsies. It also develops OV815, that focuses on the mutations associated with KIF1A-associated neurological disorder (KAND); OV888 (GV101), a highly selective rock2 inhibitor which is in Phase 1 double-blind multiple-ascending dose trial; OV825, has advanced to potential candidate lead identification for the rare neurodevelopmental condition HNRNPH2 (Bain Syndrome); and OV882, a short hairpin RNA gene therapy for the treatment of Angelman syndrome.
Ovid Therapeutics Inc. Fundamentals Summary
| 1OT fundamental statistics | |
|---|---|
| Market cap | €67.99m |
| Earnings (TTM) | -€31.15m |
| Revenue (TTM) | €605.42k |
112.3x
P/S Ratio-2.2x
P/E RatioIs 1OT overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| 1OT income statement (TTM) | |
|---|---|
| Revenue | US$631.70k |
| Cost of Revenue | US$0 |
| Gross Profit | US$631.70k |
| Other Expenses | US$33.13m |
| Earnings | -US$32.50m |
Last Reported Earnings
Sep 30, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.46 |
| Gross Margin | 100.00% |
| Net Profit Margin | -5,145.20% |
| Debt/Equity Ratio | 0% |
How did 1OT perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2024/12/23 17:39 |
| End of Day Share Price | 2024/12/20 00:00 |
| Earnings | 2024/09/30 |
| Annual Earnings | 2023/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources
Ovid Therapeutics Inc. is covered by 14 analysts. 8 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Kalpit Patel | B. Riley Securities, Inc. |
| Thomas Shrader | BTIG |
| Charles Duncan | Cantor Fitzgerald & Co. |